Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study

References

• The American Society for Aesthetic Plastic Surgery statistics Available from: http://www.surgery.org/sites/default/files/ASAPS-2011-Stats.pdfAccessed April 4, 2012
   Google Scholar
• CoxSEFinnJCSocial implications of hyperdynamic facial lines and patient satisfaction outcomesInt Ophthalmol Clin2005453132415970763
   PubMedGoogle Scholar
• FedokFGAdvances in minimally invasive facial rejuvenationCurr Opin Otolaryngol Head Neck Surg200816435936818626256
   PubMed Web of Science ®Google Scholar
• EiseleKHFinkKVeyMTaylorHVStudies on the dissociation of botulinum neurotoxin type A complexesToxicon201157455556521195107
   PubMed Web of Science ®Google Scholar
• FrevertJDresslerDComplexing proteins in botulinum toxin type A drugs: a help or a hindrance?Biologics2010432533221209727
   PubMedGoogle Scholar
• FrevertJContent of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Drugs R D2010102677320698714
   PubMedGoogle Scholar
• DresslerDAdib SaberiFNew formulation of Botox: complete antibody-induced treatment failure in cervical dystoniaJ Neurol Neurosurg Psychiatry200778110810917172580
   PubMed Web of Science ®Google Scholar
• DresslerDWohlfahrtKMeyer-RoggeEWiestLBigalkeHAntibody-induced failure of botulinum toxin a therapy in cosmetic indicationsDermatol Surg201036Suppl 42182218721134050
   PubMed Web of Science ®Google Scholar
• JankovicJVuongKDAhsanJComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystoniaNeurology20036071186118812682332
   PubMed Web of Science ®Google Scholar
• StengelGBeeEKAntibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown linesClin Interv Aging2011628128422162643
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJLoweNJOne-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar linesJ Clin Res20047120
   Google Scholar
• CarruthersJALoweNJMenterMAA multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Am Acad Dermatol200246684084912063480
   PubMed Web of Science ®Google Scholar
• CarruthersJDLoweNJMenterMAGibsonJEadieNBotoxGlabellarLinesIIStudy GroupDouble-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar linesPlast Reconstr Surg200311241089109812973229
   PubMed Web of Science ®Google Scholar
• AscherBZakineBKestemontPBaspeyrasMBougaraASantiniJA multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar linesJ Am Acad Dermatol200451222323315280841
   PubMed Web of Science ®Google Scholar
• MonheitGCarruthersABrandtFRandRA randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal doseDermatol Surg2007331 SpecS51S5917241415
   PubMed Web of Science ®Google Scholar
• ImhofMKühneUA Phase III study of incobotulinumtoxinA in the treatment of glabellar frown linesJ Clin Aesthet Dermatol2011410283422010053
   PubMedGoogle Scholar
• SattlerGCallanderMGrablowitzDNoninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesDermatol Surg201036Suppl 42146215421134045
   PubMed Web of Science ®Google Scholar
• BeerKRBoydCPatelRKBowenBJamesSPBrinMFRapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar linesJ Drugs Dermatol2011101394421197522
   PubMed Web of Science ®Google Scholar
• SchlessingerJMonheitGKaneMAMendelsohnNTime to onset of response of abobotulinumtoxinA in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type ADermatol Surg201137101434144221745254
   PubMed Web of Science ®Google Scholar
• PragerWBeeEKHavermannIZschockeIOnset, longevity and subject satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical studyClin Interv Aging2013
   Web of Science ®Google Scholar
• CarruthersACarruthersJSaidSDose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in femalesDermatol Surg200531441442215871316
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJProspective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytidsDermatol Surg200531101297130316188182
   PubMed Web of Science ®Google Scholar
• BlitzerABinderWJAvivJEKeenMSBrinMFThe management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patientsArch Otolaryngol Head Neck Surg199712343893929109785
   PubMedGoogle Scholar
• Bocouture® Summary of Product CharacteristicsMerz Pharmaceuticals GmbH2013 Available from: http://www.medicines.org.uk/emc/medicine/23251Accessed February 10, 2013
   Google Scholar
• HankeCWNarinsRSBrandtFA randomized, placebo-controlled, double-blind Phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpointDermatol Surg2013
   Google Scholar
• CarruthersACarruthersJColemanWP3rdMulticenter, randomized, Phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown linesDermatol Surg Epub242013
   Web of Science ®Google Scholar
• RzanyBFlynnTSchlöbeAHeinzMHarringtonLLong-term results for incobotulinumtoxinA in the treatment of glabellar frown linesDermatol Surg2013391 Pt 19510323190342
   PubMed Web of Science ®Google Scholar
• FlynnTCCarruthersACarruthersJValidated assessment scales for the upper faceDermatol Surg2012382 Spec30931922316187
   PubMed Web of Science ®Google Scholar
• PragerWRapplTPhase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown linesJ Cosmet Dermatol201211426727123174049
   PubMed Web of Science ®Google Scholar
• RanouxDGuryCFondaraiJMasJLZuberMRespective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystoniaJ Neurol Neurosurg Psychiatry200272445946211909903
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJBotulinum toxin products overviewSkin Therapy Lett20081361418806905
   PubMedGoogle Scholar
• Azzalure® Summary of Product CharacteristicsGalderma (UK) Ltd2013 Available from: http://www.medicines.org.uk/emc/medicine/21985Accessed February 13, 2013
   Google Scholar
• KarsaiSRaulinCCurrent evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatologyDermatol Surg20093511819018816
   PubMed Web of Science ®Google Scholar